Clinical Trials Directory

Trials / Completed

CompletedNCT03962452

Mitochondrial Diseases - Long-read Genome and Transcriptome Sequencing in Cases Unresolved After Short-read Genomics

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
20 (actual)
Sponsor
University Hospital Tuebingen · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The MiDiSeq project will enroll 20 unresolved index patients with suspected mitochondrial disease prioritized for genomic analysis.

Detailed description

In the MiDiSeq (monocentric, prospective, open-label diagnostic) project, patients with suspected mitochondrial disease prioritized for i) high a priori probability for a genetic basis (e.g. positive family history) as well as availability of (ii) fibroblast cell lines with a biochemically defined phenotype, (iii) parental samples, (iv) short read whole genome and transcriptome datasets and (v) optional additional metabolomics and proteomics data. The following questions will be leading the project: i) to systematically benchmark different sequencing technologies to detect genetic and epigenetic variation and their impact on gene regulation. (ii) to further develop algorithms for integrative analyses of different 'omics datasets. (iii) to expand the analysis from coding Single-Nucleotide Variants (SNVs) and regulatory mutations to structural variants (SVs), repeat expansions and contractions, low complexity regions and epigenetic signatures. (iv) to identify novel alterations and disease mechanisms. (v) to gain fundamental new insights into disease mechanisms and cellular biology. (vi) to improve genetic diagnostics of future rare disease patients and to evaluate personalized therapeutic options.

Conditions

Interventions

TypeNameDescription
GENETICNext Generation Sequencing (NGS)Determining the nucleic acid sequence

Timeline

Start date
2019-03-01
Primary completion
2024-02-01
Completion
2025-02-01
First posted
2019-05-24
Last updated
2025-03-30

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT03962452. Inclusion in this directory is not an endorsement.